Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia ; volume:2 ; number:1 ; day:9 ; month:12 ; year:2019 ; pages:27-31 ; date:3.2020
Clinical hematology international ; 2, Heft 1 (9.12.2019), 27-31, 3.2020
- Urheber
-
Popescu, Bogdan
Sheela, Sheenu
Thompson, Julie
Grasmeder, Sophia
Intrater, Therese
DeStefano, Christin B.
Hourigan, Christopher S.
Lai, Catherine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.2991/chi.d.191128.001
- URN
-
urn:nbn:de:101:1-2404230810295.860445246990
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Popescu, Bogdan
- Sheela, Sheenu
- Thompson, Julie
- Grasmeder, Sophia
- Intrater, Therese
- DeStefano, Christin B.
- Hourigan, Christopher S.
- Lai, Catherine
- SpringerLink (Online service)
Ähnliche Objekte (12)
Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
FLAG with Bortezomib Salvage Therapy in Relapsed/Refractory Childhood Leukemia—A Reliable Bridge to Transplantation with Limited Toxicity
Inotuzumab Ozogamicin Monotherapy as an Outpatient Salvage Treatment in Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia: Compassionate Access
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
FLAG with Bortezomib Salvage Therapy in Relapsed/Refractory Childhood Leukemia—A Reliable Bridge to Transplantation with Limited Toxicity
Inotuzumab Ozogamicin Monotherapy as an Outpatient Salvage Treatment in Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia: Compassionate Access
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
FLAG with Bortezomib Salvage Therapy in Relapsed/Refractory Childhood Leukemia—A Reliable Bridge to Transplantation with Limited Toxicity
Inotuzumab Ozogamicin Monotherapy as an Outpatient Salvage Treatment in Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia: Compassionate Access